Skin treatments developer Syntopix has signed an agreement with Sinclair Pharma.
Fully listed Sinclair specialises in skin and mouth diseases and it wants Syntopix’s help to identify “an antimicrobial compound to synergise and augment” the activity of one of its products.
The resulting product would generate revenues for both companies.
At 68.5p a share, up 2.5p, Syntopix is valued at £7.34m. Syntopix recently raised £2m at 67p a share, which left it with £2.25m in the bank.
© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.